Iguana Healthcare Management LLC lowered its holdings in shares of Juno Therapeutics Inc (NASDAQ:JUNO) by 20.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,000 shares of the biopharmaceutical company’s stock after selling 15,000 shares during the quarter. Juno Therapeutics comprises about 1.8% of Iguana Healthcare Management LLC’s investment portfolio, making the stock its 20th biggest position. Iguana Healthcare Management LLC owned approximately 0.05% of Juno Therapeutics worth $2,743,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in JUNO. The Manufacturers Life Insurance Company grew its stake in Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares during the last quarter. Advisor Group Inc. grew its stake in Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,439 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 3,559 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in Juno Therapeutics in the 4th quarter valued at $173,000. Finally, Comerica Bank acquired a new position in Juno Therapeutics in the 4th quarter valued at $240,000. Institutional investors and hedge funds own 70.19% of the company’s stock.
A number of research analysts recently issued reports on JUNO shares. Standpoint Research reiterated a “hold” rating on shares of Juno Therapeutics in a research note on Wednesday, January 24th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, January 11th. Wells Fargo reiterated a “market perform” rating and issued a $63.00 target price (up from $54.00) on shares of Juno Therapeutics in a research note on Wednesday, January 17th. Barclays lowered shares of Juno Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $55.00 to $87.00 in a research note on Wednesday, January 24th. Finally, Leerink Swann lowered shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating and raised their target price for the company from $56.00 to $87.00 in a research note on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, eighteen have issued a hold rating and two have given a buy rating to the company. Juno Therapeutics presently has an average rating of “Hold” and an average price target of $52.55.
In other news, CFO Steve Harr sold 8,750 shares of the firm’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $44.76, for a total transaction of $391,650.00. Following the completion of the transaction, the chief financial officer now directly owns 772,082 shares of the company’s stock, valued at approximately $34,558,390.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard Klausner sold 36,000 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $1,611,360.00. Following the transaction, the director now directly owns 744,392 shares of the company’s stock, valued at $33,318,985.92. The disclosure for this sale can be found here. Insiders sold a total of 471,215 shares of company stock worth $26,949,558 over the last 90 days. Company insiders own 15.08% of the company’s stock.
Shares of Juno Therapeutics stock opened at $86.96 on Monday. The company has a quick ratio of 4.77, a current ratio of 3.61 and a debt-to-equity ratio of 0.01. The stock has a market cap of $9,930.00, a price-to-earnings ratio of -16.16 and a beta of 3.24. Juno Therapeutics Inc has a 12-month low of $19.62 and a 12-month high of $87.01.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/19/iguana-healthcare-management-llc-sells-15000-shares-of-juno-therapeutics-inc-juno.html.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics Inc (NASDAQ:JUNO).
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.